This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CBT-101
Description: CBT-101 is an oral agent that targets the epithelial to mesenchymal transition (EMT) pathway that is dysregulated in several tumors. It is a highly specific inhibitor of the c-Met receptor.
CBT and Beijing Pearl
CBT retains world-wide rights to this drug outside of China. Beijing Pearl Biotechnology has rights inside of China. No additional details were disclosed.
Partners: Hengkang Medical Group Corporation Limited
Additional information available to subscribers only: